Targets › DHEAS
1 program from 1 company in 2 trials: 2 Phase 1; Genitourinary; next expected readout Jan 2027.
Open in Phaseline: the race on DHEAS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangxi University of Traditional Chinese Medicine | Bushen Yiqi Formula Adrenal steroid hormone precursor; androgen receptor agonist | DHEAS | Phase 1 | Diminished Ovarian Reserve | Jan 2027 |
Diminished Ovarian Reserve (2)
small molecule (1)
Jiangxi University of Traditional Chinese Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.